β-Cell Failure or β-Cell Abuse?

This review is motivated by the need to question dogma that has not yielded significant improvements in outcomes of Type 2 Diabetes treatment: that insulin resistance is the driver of ß-Cell failure and resulting hyperglycemia. We highlight the fact that hyperlipidemia, insulin resistance, and hyperinsulinemia all precede overt diabetes diagnosis and can each induce the other when tested experimentally. New research highlights the importance of high levels of circulating insulin as both a driver of weight gain and insulin resistance. Data from our lab and others document that several nutrients and environmental toxins can stimulate insulin secretion at non-stimulatory glucose in the absence of insulin resistance. This occurs either by direct action on the ß-Cell or by shifting its sensitivity to known secretagogues. We raise the next logical question of whether ß-Cell dysfunction in Type 2 Diabetes is due to impaired function, defined as failure, or if chronic overstimulation of the ß-Cell that exceeds its capacity to synthesize and secrete insulin, defined as abuse, is the main abnormality in Type 2 Diabetes. These questions are important as they have direct implications for how to best prevent and treat Type 2 Diabetes.

[1]  B. Zinman,et al.  Two‐year trial of intermittent insulin therapy vs metformin for the preservation of β‐cell function after initial short‐term intensive insulin induction in early type 2 diabetes , 2018, Diabetes, obesity & metabolism.

[2]  Geoffrey S Johnson,et al.  Prospective evaluation of insulin and incretin dynamics in obese adults with and without diabetes for 2 years after Roux-en-Y gastric bypass , 2018, Diabetologia.

[3]  J. Mar,et al.  Metformin regulates metabolic and nonmetabolic pathways in skeletal muscle and subcutaneous adipose tissues of older adults , 2018, Aging cell.

[4]  S. Hunt,et al.  Weight and Metabolic Outcomes 12 Years after Gastric Bypass , 2017, The New England journal of medicine.

[5]  B. Corkey,et al.  Hyperinsulinemia: a Cause of Obesity? , 2017, Current Obesity Reports.

[6]  M. Kivimaki,et al.  Trajectories of glycaemia, insulin sensitivity and insulin secretion in South Asian and white individuals before diagnosis of type 2 diabetes: a longitudinal analysis from the Whitehall II cohort study , 2017, Diabetologia.

[7]  P. Zimmet Diabetes and its drivers: the largest epidemic in human history? , 2017, Clinical Diabetes and Endocrinology.

[8]  D. Feng,et al.  Disproportionately Elevated Proinsulin Levels as an Early Indicator of β-Cell Dysfunction in Nondiabetic Offspring of Chinese Diabetic Patients , 2016, International journal of endocrinology.

[9]  D. Flum,et al.  Gastric bypass surgery vs intensive lifestyle and medical intervention for type 2 diabetes: the CROSSROADS randomised controlled trial , 2016, Diabetologia.

[10]  N. Burritt,et al.  Inhibition of Monoacylglycerol Lipase Activity Decreases Glucose-Stimulated Insulin Secretion in INS-1 (832/13) Cells and Rat Islets , 2016, PloS one.

[11]  N. Burritt,et al.  Chronic Exposure to Excess Nutrients Left-shifts the Concentration Dependence of Glucose-stimulated Insulin Secretion in Pancreatic β-Cells* , 2015, The Journal of Biological Chemistry.

[12]  M. Laakso,et al.  Both Fasting and Glucose-Stimulated Proinsulin Levels Predict Hyperglycemia and Incident Type 2 Diabetes: A Population-Based Study of 9,396 Finnish Men , 2015, PloS one.

[13]  T. Lehtimäki,et al.  Insulin and BMI as Predictors of Adult Type 2 Diabetes Mellitus , 2015, Pediatrics.

[14]  G. Dohm,et al.  Hyperinsulinemic syndrome: the metabolic syndrome is broader than you think. , 2014, Surgery.

[15]  E. Aarts,et al.  Long-Term Effects of Laparoscopic Roux-en-Y Gastric Bypass on Diabetes Mellitus, Hypertension and Dyslipidaemia in Morbidly Obese Patients , 2014, Obesity Surgery.

[16]  B. Corkey,et al.  What Are We Putting in Our Food That Is Making Us Fat? Food Additives, Contaminants, and Other Putative Contributors to Obesity , 2014, Current Obesity Reports.

[17]  R. Bergman,et al.  Variable Hepatic Insulin Clearance with Attendant Insulinemia is the Primary Determinant of Insulin Sensitivity in the Normal Dog , 2013, Obesity.

[18]  K. Thayer,et al.  Environmental Chemicals and Type 2 Diabetes: An Updated Systematic Review of the Epidemiologic Evidence , 2013, Current Diabetes Reports.

[19]  Kyla W. Taylor,et al.  Evaluation of the Association between Persistent Organic Pollutants (POPs) and Diabetes in Epidemiological Studies: A National Toxicology Program Workshop Review , 2013, Environmental health perspectives.

[20]  E. Levin,et al.  Evaluation of the Association between Maternal Smoking, Childhood Obesity, and Metabolic Disorders: A National Toxicology Program Workshop Review , 2012, Environmental health perspectives.

[21]  G. Dohm,et al.  Diabetes: Have We Got It All Wrong? , 2012, Diabetes Care.

[22]  A. Tenenbaum,et al.  Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention? , 2012, Cardiovascular Diabetology.

[23]  B. Corkey Diabetes: Have We Got It All Wrong? , 2012, Diabetes Care.

[24]  A. Tenenbaum,et al.  Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction , 2012, Cardiovascular Diabetology.

[25]  Paloma Alonso-Magdalena,et al.  Bisphenol-A acts as a potent estrogen via non-classical estrogen triggered pathways , 2012, Molecular and Cellular Endocrinology.

[26]  H. Daida,et al.  Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study , 2012, Cardiovascular Diabetology.

[27]  Terence Dwyer,et al.  Childhood adiposity, adult adiposity, and cardiovascular risk factors. , 2011, The New England journal of medicine.

[28]  S. Piccoli,et al.  Roux-en-Y gastric bypass corrects hyperinsulinemia implications for the remission of type 2 diabetes. , 2011, The Journal of clinical endocrinology and metabolism.

[29]  A. Rudich,et al.  Adolescent BMI trajectory and risk of diabetes versus coronary disease. , 2011, The New England journal of medicine.

[30]  Paloma Alonso-Magdalena,et al.  Endocrine disruptors in the etiology of type 2 diabetes mellitus , 2011, Nature Reviews Endocrinology.

[31]  W. Willett,et al.  Childhood Size and Life Course Weight Characteristics in Association With the Risk of Incident Type 2 Diabetes , 2010, Diabetes Care.

[32]  Hui-yu Liu,et al.  Increased basal level of Akt-dependent insulin signaling may be responsible for the development of insulin resistance. , 2009, American journal of physiology. Endocrinology and metabolism.

[33]  Mika Kivimäki,et al.  Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study , 2009, The Lancet.

[34]  S. Colagiuri,et al.  Bimodal Distribution of Glucose Is Not Universally Useful for Diagnosing Diabetes , 2009, Diabetes Care.

[35]  B. Strom,et al.  Antidiabetic Action of Bezafibrate in a Large Observational Database , 2009, Diabetes Care.

[36]  R. Bergman,et al.  Metabolic syndrome, hyperinsulinemia, and cancer. , 2007, The American journal of clinical nutrition.

[37]  D. Tanné,et al.  Long-term effect of bezafibrate on pancreatic beta-cell function and insulin resistance in patients with diabetes. , 2007, Atherosclerosis.

[38]  M. Zdravkovic,et al.  The effects of NN414, a SUR1/Kir6.2 selective potassium channel opener in subjects with type 2 diabetes. , 2007, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[39]  H. Jörnvall,et al.  The possible mechanisms by which phanoside stimulates insulin secretion from rat islets. , 2007, The Journal of endocrinology.

[40]  T. Jones,et al.  Increasing body mass index z-score is continuously associated with complications of overweight in children, even in the healthy weight range. , 2007, The Journal of clinical endocrinology and metabolism.

[41]  Y. Iwamoto,et al.  Serum proinsulin levels at fasting and after oral glucose load in patients with Type 2 (non-insulin-dependent) diabetes mellitus , 1988, Diabetologia.

[42]  J. Fruchart,et al.  Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. , 2006, Drugs of today.

[43]  J. Kushner,et al.  Very Slow Turnover of β-Cells in Aged Adult Mice , 2005 .

[44]  T. Dyrberg,et al.  The Effects of NN414, a SUR1/Kir6.2 Selective Potassium Channel Opener, in Healthy Male Subjects , 2005, Journal of clinical pharmacology.

[45]  Masafumi Matsuda,et al.  beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. , 2005, The Journal of clinical endocrinology and metabolism.

[46]  V. Grill,et al.  Openers of ATP-dependent K+-channels protect against a signal-transduction-linked and not freely reversible defect of insulin secretion in a rat islet transplantation model of Type 2 diabetes , 2004, Diabetologia.

[47]  J. Sturis,et al.  Attenuation of hyperinsulinemia by NN414, a SUR1/Kir6.2 selective K-adenosine triphosphate channel opener, improves glucose tolerance and lipid profile in obese Zucker rats. , 2004, Metabolism: clinical and experimental.

[48]  Johannes D. Veldhuis,et al.  Induction of β-cell rest by a Kir6.2/SUR1-selective KATP-Channel opener preserves β-cell insulin stores and insulin secretion in human islets cultured at high (11 mM) glucose , 2004 .

[49]  M. Matsuda,et al.  Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man , 1994, Diabetologia.

[50]  T. M. Szopa,et al.  Coxsackie B4 viruses with the potential to damage Beta cells of the islets are present in clinical isolates , 1990, Diabetologia.

[51]  J. Sturis,et al.  NN414, a SUR1/Kir6.2-selective potassium channel opener, reduces blood glucose and improves glucose tolerance in the VDF Zucker rat. , 2003, Diabetes.

[52]  C. Bogardus,et al.  A high fasting plasma insulin concentration predicts type 2 diabetes independent of insulin resistance: evidence for a pathogenic role of relative hyperinsulinemia. , 2000, Diabetes.

[53]  N. Porksen,et al.  Overnight inhibition of insulin secretion restores pulsatility and proinsulin/insulin ratio in type 2 diabetes. , 2000, American journal of physiology. Endocrinology and metabolism.

[54]  R. Vigneri,et al.  Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta-cells. , 2000, Diabetes.

[55]  M. Zemel,et al.  Diazoxide down‐regulates leptin and lipid metabolizing enzymes in adipose tissue of Zucker rats , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[56]  P. Jones,et al.  Gymnema sylvestre stimulates insulin release in vitro by increased membrane permeability. , 1999, The Journal of endocrinology.

[57]  G. Boden,et al.  Acute lowering of plasma fatty acids lowers basal insulin secretion in diabetic and nondiabetic subjects. , 1998, Diabetes.

[58]  R. Alemzadeh,et al.  Beneficial effect of diazoxide in obese hyperinsulinemic adults. , 1998, The Journal of clinical endocrinology and metabolism.

[59]  P. Halban,et al.  Proinsulin Conversion in GH3 Cells After Coexpression of Human Proinsulin With the Endoproteases PC2 and/or PC3 , 1997, Diabetes.

[60]  R. Alemzadeh,et al.  Antiobesity effect of diazoxide in obese Zucker rats. , 1996, Metabolism: clinical and experimental.

[61]  G. Boden,et al.  Effects of a 48-h Fat Infusion on Insulin Secretion and Glucose Utilization , 1995, Diabetes.

[62]  G. Boden,et al.  Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes. , 1995, The Journal of clinical investigation.

[63]  S. Woods,et al.  Intraventricular insulin and the level of maintained body weight in rats. , 1995, Behavioral neuroscience.

[64]  J. Leahy,et al.  Increased secretory demand rather than a defect in the proinsulin conversion mechanism causes hyperproinsulinemia in a glucose-infusion rat model of non-insulin-dependent diabetes mellitus. , 1995, The Journal of clinical investigation.

[65]  L. Rossetti,et al.  Mechanisms of fatty acid-induced inhibition of glucose uptake. , 1994, The Journal of clinical investigation.

[66]  P. Halban,et al.  Kinetics of Proinsulin Conversion in Human Islets , 1993, Diabetes.

[67]  T. Castonguay,et al.  Effect of chronic insulin administration on food intake and body weight in rats , 1991, Physiology & Behavior.

[68]  S. Woods,et al.  Central insulin administration reduces neuropeptide Y mRNA expression in the arcuate nucleus of food-deprived lean (Fa/Fa) but not obese (fa/fa) Zucker rats. , 1991, Endocrinology.

[69]  M. Goubern,et al.  Concomitant food intake and adipose tissue responses under chronic insulin infusion in rats , 1988, Physiology & Behavior.

[70]  K. Polonsky,et al.  Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. , 1988, The Journal of clinical investigation.

[71]  W. Blackard,et al.  Down regulation of insulin receptors in primary cultures of adult rat hepatocytes in monolayer. , 1978, Endocrinology.

[72]  M. Laudat,et al.  [Decreased number of insulin receptors in obesity: studies in the obese hyperglycemic mouse (author's transl)]. , 1976, Annales d'endocrinologie.

[73]  C. Hales,et al.  IMPROVEMENT IN INSULIN SECRETION IN DIABETES AFTER DIAZOXIDE , 1976, The Lancet.

[74]  W. Blackard,et al.  Proinsulin, insulin, and C-peptide concentrations in human portal and peripheral blood. , 1975, The Journal of clinical investigation.

[75]  D. Neville,et al.  Insulin-dependent regulation of insulin receptor concentrations: a direct demonstration in cell culture. , 1974, Proceedings of the National Academy of Sciences of the United States of America.